Slide 1WE ARE EARLY PHASESlide 2TRIAL EXPERTISESlide 3THERAPEUTIC EXPERTISE We are EARLY Phase We do one thing only, and we do it reliably in all shapes and colours – even yours. FIND OUT WHO WE ARE Trial Expertise We deliver reliable research on everything first-in-human. And we do it in every relevant field and in our own clinical facilities. LEARN ABOUT OUR METHODOLOGIES Therapeutic EXPERTISE Our specialised units in 4 locations handle indications that range from cardiovascular to respiratory. SEE OUR EXPERTISE BY INDICATION News Scientific News Check out the study “Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects” Scientific News Thieme: Diabetes mellitus und Herz Company News CRS Berlin in the headlines 📢 Igyxos Initiates Phase 1 Clinical Trials for IGX12: A Breakthrough Treatment for Infertility Company News Netzwerkabend am 26.10.2023 bei CRS in Mannheim Company News The exciting Diabetes Live program „Post EASD 2023“ Company News Meet us at EASD 2023 in Hamburg, Germany, from 2 to 6 October 🌟 More News Publications Investigative Radiology Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults Pharmacology Research & Perspectives Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects Cardiovasc Diabetology CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Metabolism Clinical and Experimental Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Journal of Clinical Pharmacology (Bersacapavir) In Participants With Moderate Hepatic Impairment. ESC Heart Failure Journal Discordance between estimated and measured changes in plasma volume among patients with acute heart failure. More Publications Studies in cooperation with: REACHING OUT IS EASY AND FAST – LET’S TALK Prof. Dr. Thomas Forst Chairman of the Executive Board LET’S TALK SCIENCE *protected email* +49 621 150 45 – 0 Martin Mulder Senior Vice President Corporate & Business Development LET’S TALK BUSINESS *protected email* +49 621 150 45 – 0 CRO Leadership Awards 2019 CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability. European Biotechnology Guide Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019. EcoVadis – CSR Rating Based on the CSR rating by EcoVadis in 2022 CRS has been granted Silver Recognition Level.